Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales

AI Summary

Eli Lilly (LLY) reported sales of $12.9 billion from its GLP-1 drugs every three months. The company stated that the tirzepatide franchise had a strong quarter, indicating significant market demand. This growth reflects the increasing adoption of these drugs as part of diabetes treatment. The positive sales performance could impact investor sentiment and market positioning for LLY as it continues to expand in the pharmaceutical sector.